7-chloro-2-oxo-1,2-dihydroquinoline-4-carboxylic acid | 32431-34-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-chloro-2-oxo-1,2-dihydroquinoline-4-carboxylic acid
• 英文别名: 7-chloro-2-oxo-1H-quinoline-4-carboxylic acid
• CAS: 32431-34-8
• 化学式: C₁₀H₆ClNO₃
• 分子量: 223.616
• InChiKey: UOGDRGQUIULLFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-chloro-2-oxo-1,2-dihydroquinoline-4-carboxylic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 7-chloro-4-(morpholine-4-carbonyl)quinolin-2-yltrifluoromethanesulfonate
  参考文献：
  名称：

  WO2024072870A1

  摘要：

  公开号：
• 作为产物：
  描述：

  6-氯吲哚 在 aluminum (III) chloride 、 silica gel 、 溶剂黄146 、 pyridinium chlorochromate 作用下， 生成 7-chloro-2-oxo-1,2-dihydroquinoline-4-carboxylic acid
  参考文献：
  名称：

  Synthesis and biological evaluation of novel 2-oxo-1,2-dihydroquinoline-4-carboxamide derivatives for the treatment of esophageal squamous cell carcinoma

  摘要：

  No new and effective treatments have been approved for the treatment of esophageal squamous cell carcinoma (ESCC) in the past decade. Cisplatin and 5-fluoruracil are the most commonly used drugs for this disease. In order to develop a new class of drugs effective in our ESCC phenotypic screens, we began a systematic approach to generate novel compounds based on the 2-oxo-1,2-dihydroquinoline-4carboxamide fragment. Herein, we report on the synthesis and initial assessment of 55 new analogues in two ESCC cell lines. Some of the active analogues with 1050 values around 10 mu M were tested in three additional cell lines. Our structure-activity relationships revealed remarkable alterations in the anti proliferative activities upon modest chemical modifications and autophagy modulation is a suggested mechanism of action. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.05.042

文献信息

• Enantioselective, Intermolecular [_π2+_σ2] Photocycloaddition Reactions of 2(1<i>H</i>)-Quinolones and Bicyclo[1.1.0]butanes
  作者：Morgane de Robichon、Thilo Kratz、Frederike Beyer、Julian Zuber、Christian Merten、Thorsten Bach

  DOI：10.1021/jacs.3c08404

  日期：——

  enantioselectively to 2(1H)-quinolones upon irradiation (λ = 366 nm) in the presence of a chiral complexing agent. A two-point hydrogen bond between the quinolone and the template is responsible for stereocontrol in the photocycloaddition reaction. The reaction leads to the formation of products with a chiral bicyclo[2.1.1]hexane skeleton in high enantiomeric excess (91–99% ee). The chiral template can be almost

  在手性络合剂存在下，经照射 (λ = 366 nm)，1-取代的双环[1.1.0]丁烷对映选择性地加成到 2(1 H )-喹诺酮类药物上。喹诺酮和模板之间的两点氢键负责光​​环加成反应中的立体控制。该反应导致形成具有高对映体过量（91-99% ee）的手性双环[2.1.1]己烷骨架的产物。手性模板几乎可以定量（97%）回收并用于另一个反应。可能存在三重态反应途径，如果反应要在可见光 (λ = 420 nm) 下进行，则敏化是一个合适的工具。
• Synthesis and biological evaluation of novel 2-oxo-1,2-dihydroquinoline-4-carboxamide derivatives for the treatment of esophageal squamous cell carcinoma
  作者：Mai I. Shahin、Joyeeta Roy、Maha Hanafi、Dongyao Wang、Urarika Luesakul、Yifeng Chai、Nongnuj Muangsin、Deena S. Lasheen、Dalal A. Abou El Ella、Khaled A. Abouzid、Nouri Neamati

  DOI：10.1016/j.ejmech.2018.05.042

  日期：2018.7

  No new and effective treatments have been approved for the treatment of esophageal squamous cell carcinoma (ESCC) in the past decade. Cisplatin and 5-fluoruracil are the most commonly used drugs for this disease. In order to develop a new class of drugs effective in our ESCC phenotypic screens, we began a systematic approach to generate novel compounds based on the 2-oxo-1,2-dihydroquinoline-4carboxamide fragment. Herein, we report on the synthesis and initial assessment of 55 new analogues in two ESCC cell lines. Some of the active analogues with 1050 values around 10 mu M were tested in three additional cell lines. Our structure-activity relationships revealed remarkable alterations in the anti proliferative activities upon modest chemical modifications and autophagy modulation is a suggested mechanism of action. (C) 2018 Elsevier Masson SAS. All rights reserved.
• WO2024072870A1
  申请人：——

  公开号：——

  公开（公告）日：——